Tag Archives: CROI 2017

The PHCN’s News in Review Newsletter (13/03/17)

The PHCN's News in Review Newsletter (13/03/17)Welcome to the Pacific Hepatitis C Network (PHCN)‘s Hepatitis C News in Review Newsletter. This is where we review all of the major current issues and events around hepatitis C and hep C treatments. It is an email that includes links to our recent blog posts—including links to blog posts about the BC Ministry of Health announcing that they are now covering additional hepatitis C treatments.

PHCN’S STATEMENT ABOUT THE SUCCESSFUL NEGOTIATIONS FOR 3 NEW HEPATITIS C TREATMENTS

‘No One Left Behind!’

Pacific Hepatitis C Network (PHCN) is very happy to learn that effective March 21, an extensive list of hepatitis C treatments will be available through BC PharmaCare – at far better prices than they previously had been. The high cost of hepatitis C treatment has effectively restricted the numbers of people living with hepatitis C who could access treatment…

BC MINISTRY OF HEALTH COVERS ADDITIONAL HEPATITIS C TREATMENTS

Agreements between the pCPA and Gilead Sciences Canada, Merck Canada, and Bristol-Myers Squibb Canada were reached to provide several hepatitis C drugs at an improved cost:

  • Daklinza (daclatasvir) – new
  • Epclusa (sofosbuvir/velpatasvir) – new
  • Harvoni (ledipasvir/sofosbuvir)
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir) – new
  • Zepatier (elbasvir/grazoprevir) – new

BC MINISTRY OF HEALTH ANNOUNCES END OF LIVER FIBROSIS F1> TREATMENT REQUIREMENT

PharmaCare announced that starting in 2018-19, they will provide coverage for any British Columbian living with chronic hepatitis C, regardless of the type or severity of their disease.

ONTARIO DRUG BENEFIT PROGRAM FUNDING HEPATITIS C DRUGS

Effective February 28, 2017, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.

• Harvoni (ledipasvir/sofosbuvir)
• Sovaldi (sofosbuvir)
• Epclusa (sofosbuvir/velpatasvir)
• Zepatier (elbasvir/grazoprevir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir)
• Ibavyr (ribavirin)

CROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings. The following blog posts highlight HIV/HCV information that was at the conference.

REFLECTIONS BY PHCN’S PRESIDENT DARYL LUSTER

For more information about the topics in this newsletter, please click on the links, visit PHCN’s Hepatitis C Treatment Information Project, or email us.

CROI 2017 by Lucinda K. Porter, RN

CROI 2017 by Lucinda K. Porter, RNLucinda K. Porter

This is a collection of blog posts written by Lucinda K. Porter, RN, a hepatitis C writer who attended this year’s Conference on Retroviruses and Opportunistic Infections (CROI). The blog posts below highlight hepatitis C studies presented at the conference that stood out to her.

Please scroll down and click on the blog tittles that interest you.

Sampling of CROI 2017 Meeting Highlights Written by Lucinda K. Porter, RN

CROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.

More information about the CROI and the studies that were presented there can also be found in our blog post CROI 2017 Hep C Highlights Part I.

“Creating a world free from hepatitis C one step at a time” -Lucinda Porter

CROI 2017 Hep C Highlights Part II

CROI 2017 Hep C (HCV) HighlightsCROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.

This blog post is a collection of HIV/HCV highlights that were presented at CROI 2017. Please scroll down and click on the subjects that interest you.

More Interesting CROI 2017 Abstracts about HIV/HCV Coinfection

More information about The Conference on Retroviruses and Opportunistic Infections (CROI), or these and other studies can be found in our blog post CROI 2017 Hep C Highlights Part I or on the conference’s website.

CROI 2017 Hep C Highlights Part I

CROI 2017 Hep C Highlights Part ICROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.

This blog post is a collection of HIV/HCV highlights that were presented. Please scroll down and click on the subjects that interest you.

Interesting Meeting Abstracts about HIV/HCV Coinfection

More information about The Conference on Retroviruses and Opportunistic Infections (CROI), or these and other studies can be found in our blog post CROI 2017 Hep C Highlights Part II or on the conference’s website.